hackint0sh/New-Dataset huggingface dataset:
The vaccine will be administered with 2-dose schedule, intramuscularly, with 28 day interval. count: 400 type: ESTIMATED name: INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 µg measure: Vaccine Neutralizing Antibody Profile measure: Incidence of Adverse Events measure: Humoral Immunogenicity - The Neutralizing Antibody Titers in Serum measure: Humoral Immunogenicity - Levels of SARS-CoV-2 Binding Antibodies by CLIA measure: Cellular Immunogenicity Profile measure: Persistence of Antibody Level measure: Whole Genome Sequencing (WGS) of SARS-CoV-2 sex: FEMALE minimumAge: 12 Years maximumAge: 17 Years stdAges: CHILD facility: Dr. Soetomo General Hospital status: RECRUITING city: Surabaya state: Jawa Timur zip: 67161 country: Indonesia name: Dominicus Husada, MD role: CONTACT phone: +6281232266377 email: dominicushusada@yahoo.com name: Damayanti Tinduh, MD role: CONTACT phone: +6281703293335 email: damayanti.tinduh@fk.unair.ac.id name: Dominicus Husada, MD role: PRINCIPAL_INVESTIGATOR name: Damayanti Tinduh, MD role: SUB_INVESTIGATOR name: Gatot Soegiarto, MD role: SUB_INVESTIGATOR name: Leny Kartina, MD role: SUB_INVESTIGATOR name: Laksmi Wulandari, MD role: SUB_INVESTIGATOR name: Deasy Fetarayani, MD role: SUB_INVESTIGATOR name: Novira Widajanti, MD role: SUB_INVESTIGATOR name: Yudi H Oktaviano, MD role: SUB_INVESTIGATOR name: Aryati Aryati, MD role: SUB_INVESTIGATOR name: Fitriah Munawaroh, MD role: SUB_INVESTIGATOR name: Neneng D Kurniati, MD role: SUB_INVESTIGATOR name: Budi Utomo, MD role: SUB_INVESTIGATOR name: Eko B Khoendori, MD role: SUB_INVESTIGATOR name: Jusak Nugroho, MD role: SUB_INVESTIGATOR name: Maria I Lusida, MD role: SUB_INVESTIGATOR lat: -7.24917 lon: 112.75083 hasResults: False
nctId: NCT06282679 id: KY20220701-03 briefTitle: Clinical Observation of Botulinum Toxin A Treatment in the Treatment of Rosacea overallStatus: RECRUITING date: 2022-04-01 date: 2024-03-01 date: 2024-06-28 date: 2024-02-28 date: 2024-02-28 name: Nanjing First Hospital, Nanjing Medical University class: OTHER briefSummary: the goal of this study is to study the clinical efficacy and safety of botox in the treatment of rosacea. conditions: Rosacea conditions: Botulinum Toxin studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Botulinum Toxin Type A Injection [Botox] measure: CEA score measure: GAIS score measure: VISIA red zone score measure: Dermatology Quality of Life Score (DLQI) sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Jie Dai status: RECRUITING city: Nanjing state: Jiangsu zip: 210006 country: China name: jie dai role: CONTACT phone: 02552271117 email: karry_dj@126.com lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06282666 id: KE-0254/150/2019 briefTitle: Lumbar ESPB in Hip Replacement Surgery acronym: ESPB_HIP overallStatus: NOT_YET_RECRUITING date: 2024-02-19 date: 2025-02-01 date: 2025-08-01 date: 2024-02-28 date: 2024-02-28 name: Medical University of Lublin class: OTHER briefSummary: In this study, continuous erector spinae plane block (ESPB) will be compared to continuous epidural analgesia in patients undergoing elective hip replacement surgery. Opioid consumption, pain severity, quadriceps femoris muscle strength, ability to walk, and quality of recovery will be evaluated. Moreover, chronic pain severity in months after the hospital discharge will be assessed. conditions: Coxarthrosis conditions: Pain, Postoperative conditions: Pain, Acute conditions: Pain, Chronic conditions: Postoperative Pain, Chronic conditions: Analgesia conditions: Quality of Life conditions: Anesthesia conditions: Spinal studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Two groups will be randomly allocated to Epidural and ESPB (1:1) primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Participants will not be aware of the type of continuous blockade. Care providers, including doctors and nurses, will not be aware of patient allocation.
Physiotherapists assessing outcomes will not be aware of patient allocation. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Spinal anesthesia name: lumbar erector spinae plane block name: Epidural analgesia name: patient-controlled analgesia name: Timed Up and Go test name: neuropathic pain symptom inventory name: Lovett test name: Visual analog scale name: Quality of Recovery 40 name: Ability to sit, stand upright, and walk measure: Opiod consumtion with PCA measure: Pain at rest measure: Pain upon activity measure: Lovett test measure: TUG measure: QoR-40 measure: NPSI sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: II Department of Anesthesia and Intensive Care city: Lublin zip: 20-081 country: Poland name: Michał A Borys, M.D. Ph.D role: CONTACT phone: 506350569 phoneExt: +48 email: michalborys1@gmail.com name: Paweł Kutnik, M.D. role: CONTACT phone: 608769410 phoneExt: +48 email: pe.kutnik@gmail.com lat: 51.25 lon: 22.56667 hasResults: False
nctId: NCT06282653 id: Endo-ergonomics briefTitle: Postural and Muscle Fatigue Analysis of Endodontic Residents overallStatus: RECRUITING date: 2024-04-30 date: 2025-06-30 date: 2025-11-01 date: 2024-02-28 date: 2024-02-28 name: Universidad Europea de Madrid class: OTHER briefSummary: Musculoskeletal disorders (MSDs) are a significant occupational health problem for dentists and have been linked to a decline in quality of life, often leading to stress-related illnesses and early retirement. Poor posture, poor movement or imbalances in the neck or shoulders can lead to the three most common pain syndromes in dentistry. The objectives of this study were to evaluate the working position adopted during an endodontic procedure and to determine the perception of symptoms of musculoskeletal disorders in first and second year students of the Master in Advanced Endodontics at the European University of Madrid (UEM), using the standardised Nordic Kuorinka questionnaire supplemented by a form with socio-demographic variables. This study has a descriptive cross-sectional observational design and included 10 students selected by convenience sampling. A video camera was used to record the procedures from three different angles for a maximum of 5 minutes. The information was processed using Microsoft Excel spreadsheet software, and the video recordings were assessed using Rodgers' Muscular Fatigue Analysis (RMFA) and Rapid Upper Limb Assessment (RULA). conditions: Musculoskeletal System Disease conditions: Position Sense Disorders conditions: Symptoms and Signs conditions: Postural; Defect conditions: Endodontic Disease studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: OTHER count: 10 type: ESTIMATED measure: Symptom Perception sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Universidad Europea de Madrid status: RECRUITING city: Villaviciosa De Odón state: Madrid country: Spain name: Antonio Conde, PhD role: CONTACT lat: 40.35692 lon: -3.90011 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-02-20 uploadDate: 2024-02-20T05:22 filename: Prot_000.pdf size: 96217 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-02-20 uploadDate: 2024-02-20T05:30 filename: ICF_001.pdf size: 77805 hasResults: False
nctId: NCT06282640 id: 567 briefTitle: Comparıson Of Electromyography Results Before And After Vıtamın D Treatment In Patıents Wıth Carpal Tunnel Syndrome overallStatus: COMPLETED date: 2021-12-30 date: 2022-06-30 date: 2022-08-30 date: 2024-02-28 date: 2024-02-28 name: Dr. Ayşe Güç class: OTHER_GOV name: Kayseri City Hospital briefSummary: Therefore, we aimed to evaluate the effectiveness of vitamin D replacement therapy on pain, electrophysiological parameters, ultrasonographic measurement results and functional status scales in CTS patients with low serum vitamin D levels. conditions: Carpal Tunnel Syndrome conditions: Vitamin D Deficiency studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 87 type: ACTUAL name: Vitamin D measure: electrophysiological scale. measure: monofilament test measure: Boston symptom severity scale sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kayseri City Hospital city: Kayseri country: Turkey lat: 38.73222 lon: 35.48528 hasResults: False
nctId: NCT06282627 id: 10430012010023 briefTitle: The COVID HOME Study: Prospective Cohort Study of Non-hospitalised COVID-19 Patients acronym: COVID-HOME overallStatus: COMPLETED date: 2020-03-20 date: 2022-07-30 date: 2022-08-30 date: 2024-02-28 date: 2024-02-28 name: University Medical Center Groningen class: OTHER name: ZonMw: The Netherlands Organisation for Health Research and Development briefSummary: Background. Guidelines on COVID-19 management are developed as we learn from this pandemic. However, most research has been done on hospitalised patients and the impact of the disease on non-hospitalised and their role in transmission are not yet well understood.
Methods. An ongoing prospective longitudinal observational study of COVID-19 outpatients was established in March 2020 at the beginning of the COVID-19 pandemic in the Netherlands. Laboratory confirmed SARS-CoV-2 infected individuals of all ages that did not merit hospitalisation, and their household (HH) members, were enrolled after written informed consent. Enrolled participants were visited at home within 48 hours after initial diagnosis, and then weekly on days 7, 14 and 21 to obtain clinical data, a blood sample for biochemical parameters/cytokines and serological determination; and a nasopharyngeal/throat swab plus urine, stool and sperm or vaginal secretion (if consenting) to test for SARS-CoV-2 by RT-PCR (viral shedding) and for viral culturing. Weekly nasopharyngeal/throat swabs and stool samples, plus a blood sample on days 0 and 21 were also taken from HH members to determine whether and when they became infected. All participants were invited to continue follow-up at 3-, 6-, 12- and 18-months post-infection to assess long-term sequelae and immunological status. conditions: COVID-19 conditions: Post-COVID-19 Syndrome studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 256 type: ACTUAL name: Observational study measure: SARS-CoV-2 infection measure: Long-term sequelae sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University Medical Center Groningen city: Groningen zip: 9713 GZ country: Netherlands lat: 53.21917 lon: 6.56667 hasResults: False
nctId: NCT06282614 id: MUCO245 id: 2023-A02081-44 type: OTHER domain: ID-RCB briefTitle: Performance and Safety of MUCOGYNE® Ovule as a Moisturizer acronym: MOVHYDA overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2025-01 date: 2024-02-28 date: 2024-02-28 name: Biocodex class: INDUSTRY name: Voisin Consulting Life Science (VCLS) briefSummary: The aim of this post-Market Clinical Follow-up (PMCF) study is to confirm the efficacy and safety of MUCOGYNE® Ovule in the maintainance of natural moisture of the vulvovaginal mucosa and in the compensation for any natural secretions deficiencies, when used in accordance with its approved labeling, in the context of vulvovaginal dryness. conditions: Vaginal Dryness studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective, multicenter (France), open label without comparator study primaryPurpose: OTHER masking: NONE count: 50 type: ESTIMATED name: Mucogyne Ovule measure: Assessment of the efficacy of MUCOGYNE® Ovule intra vaginal applications on subjects' vaginal dryness irrespective of the cause over a 35-day period of use measure: Assessment of the local performance of MUCOGYNE® Ovule in reducing vulva irritation measure: Assessment of the local performance of MUCOGYNE® Ovule in reducing vulvo-vaginal discomfort measure: Assessment of the local performance of MUCOGYNE® Ovule in reducing itching measure: Assessment of the local performance of MUCOGYNE® Ovule in reducing pain and/or dyspareunia related to vaginal dryness measure: Assessment of the patient's sexual function measure: Assessment of the patient's satisfaction measure: Assessment of changes in patient's clinical status measure: Assessment by investigator of changes in patient's clinical status measure: Assessment of the safety of MUCOGYNE® Ovule measure: Assessment of the device deficiencies of MUCOGYNE® Ovule measure: Assessment of the usability of MUCOGYNE® Ovule sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: JEAN Christian's medical office city: Nogent-sur-Marne zip: 94130 country: France lat: 48.83333 lon: 2.48333 facility: Dr Ramez GHADRI's medical office city: Orléans zip: 45100 country: France name: Ramez GHADRI, MD role: CONTACT name: Ramez GHADRI, MD role: PRINCIPAL_INVESTIGATOR lat: 47.90289 lon: 1.90389 facility: Dr Raïssa APERANO-MAS's medical office city: Rennes zip: 35000 country: France name: Raïssa APERANO-MAS, MD role: CONTACT name: Raïssa APERANO-MAS, MD role: PRINCIPAL_INVESTIGATOR lat: 48.11198 lon: -1.67429 hasResults: False
nctId: NCT06282601 id: GUIGOU - Defaye 2023 briefTitle: STUDY OF THE EFFECT OF RHYTHMIC AND NON-RHYTHMIC MUSICAL PRIMING ON THE SYNTAX CAPACITY OF PRESBYACOUSTIC OLDER ADULTS acronym: AMORCAGE MUSIC overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-03 date: 2024-03 date: 2024-02-28 date: 2024-02-28 name: Centre Hospitalier Universitaire Dijon class: OTHER briefSummary: Presbyacusis, or age-related hearing loss, is a public health problem, affecting 20% of men and 30% of women over the age of 70 according to the WHO. In the most incapacitating cases, hearing aids are required. Numerous studies have evaluated the benefits of hearing aids, particularly in terms of improved hearing and quality of life.
This study is based on the hypothesis that music priming with regular music optimizes the syntax language skills of people with presbyacusis, as has already been proven in adults and normal-hearing children. conditions: Presbyacousie studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 27 type: ESTIMATED name: Audiogram name: Musical priming for the syntax test name: Test MMSE name: Barcelona Music Reward Questionnaire measure: linguistic performance test focusing on syntax. sex: ALL minimumAge: 70 Years stdAges: OLDER_ADULT hasResults: False
nctId: NCT06282588 id: CTO21042GZA briefTitle: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers acronym: THUNDER overallStatus: RECRUITING date: 2023-12-13 date: 2030-07-31 date: 2030-12-31 date: 2024-02-28 date: 2024-02-28 name: Cancer Research Antwerp class: OTHER name: Bayer name: Veracyte, Inc. briefSummary: This Investigator-initiated, Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) study will be conducted in subjects with high-risk localized or locally advanced prostate cancer (PCa). The study contains both a randomized Phase 3 treatment intensification study, as well as a treatment de-intensification non-randomized Phase 2 study. The aim of the THUNDER study is to improve the outcome of high-risk PCa by improved risk stratification. Novel radiotracers and a genomic classifier (Decipher) will be used to guide treatment decisions, instead of standard imaging which is limited by lower sensitivity and specificity.
The hypothesis for the study is that treatment intensification based on a positive PSMA PET/ CT scan or Decipher high score (\> 0.6) improves time to new metastases detected on PSMA PET/ CT in high-risk PCa. In patients who are PSMA PET/ CT negative with a low/ intermediate Decipher score (≤ 0.6), it is hypothesized that treatment de-intensification will improve patient quality of life while maintaining a good oncological outcome.
nctId: NCT06282562 id: NL84223.018.23 briefTitle: FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients acronym: FeelFit overallStatus: RECRUITING date: 2024-03 date: 2026-08-15 date: 2026-08-15 date: 2024-02-28 date: 2024-03-06 name: Amsterdam UMC, location VUmc class: OTHER briefSummary: The FeelFit study aims to assess the effectiveness of High-Intensity Interval Training (HIIT) in improving self-reported physical fitness in adult brain tumor patients during periods of stable disease, as compared to a waiting-list control group. Furthermore, several secondary and exploratory outcomes will be evaluated. The study is part of the GRIP (GuaRding quality survivorshiP) project, which aims to improve quality of life in brain tumor patients. conditions: Brain Tumor, Primary conditions: Exercise studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 36 type: ESTIMATED name: High-Intensity Interval Training (HIIT) measure: Self-reported physical fitness measure: Self-reported fitness measure: VO2max measure: Daily physical activity measure: Health-related quality of life questionnaire measure: Perceived functional impairments measure: Self-efficacy measure: Mastery measure: Brain tumor specific quality of life questionnaire measure: Subjective Happiness measure: Subjective cognitive functioning measure: Subjective cognitive failure measure: Fatigue questionnaire measure: Sleep questionnaire measure: Anxiety questionnaire measure: Self-reported depression questionnaire measure: Depression questionnaire measure: Muscle strength measure: Subjective physical fitness measure: Objective neurocognitive functioning measure: Objective neurological functioning measure: Brain imaging (optional) measure: Brain activity (optional) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: VU University Medical Centers, location VUmc status: RECRUITING city: Amsterdam zip: 1081 HV country: Netherlands name: Marieke Blom, Msc role: CONTACT phone: +31621522442 email: gripopfitheid@amsterdamumc.nl lat: 52.37403 lon: 4.88969 hasResults: False
nctId: NCT06282549 id: YMC046 briefTitle: Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension overallStatus: RECRUITING date: 2022-06-08 date: 2027-03-31 date: 2027-03-31 date: 2024-02-28 date: 2024-02-28 name: Yuhan Corporation class: INDUSTRY briefSummary: This study is to develop a predictive model for cardiocerebrovascular risk factors in elderly patients with essential hypertension with Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination. conditions: Essential Hypertension studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1210 type: ESTIMATED name: Telmisartan/Amlodipine/Chlorthalidone(Truset) measure: Percentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events) measure: Percentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events) in patients with asymptomatic target organ damage measure: Mean Systolic Blood Pressure (MSBP)/ Diastolic Blood Pressure (MDBP) measure: Patients Achieving the treatment goal in Mean Systolic Blood Pressure (MSBP) measure: Percentage of patients who terminated the treatment sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Busan Veterans Hospital status: RECRUITING city: Busan zip: 46996 country: Korea, Republic of name: Jonghyun Choi role: CONTACT lat: 35.10278 lon: 129.04028 facility: Daegu Veterans Hospital status: RECRUITING city: Daegu zip: 42835 country: Korea, Republic of name: Sangwook Kang role: CONTACT lat: 35.87028 lon: 128.59111 facility: Gwangju Veterans Hospital status: RECRUITING city: Gwangju zip: 62284 country: Korea, Republic of name: Seowon Choi role: CONTACT lat: 35.15472 lon: 126.91556 facility: Konkuk University Medical Center status: RECRUITING city: Seoul zip: 05030 country: Korea, Republic of name: Chanhee Kwon role: CONTACT lat: 37.566 lon: 126.9784 facility: Veterans Health Service Medical Center status: RECRUITING city: Seoul zip: 05368 country: Korea, Republic of name: Changhoon Lee role: CONTACT lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06282536 id: LungMate-018 briefTitle: Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-06 date: 2029-12 date: 2024-02-28 date: 2024-02-28 name: Shanghai Pulmonary Hospital, Shanghai, China class: OTHER briefSummary: Fusion of anaplastic lymphoma kinase (ALK) is an important driving gene for NSCLC, with an incidence rate of 3-7%. In patients with advanced ALK mutation NSCLC, first-line use of ALK inhibitors significantly improves progression free survival. The perioperative research on ALK positive NSCLC was relatively late, and currently most studies mainly focus on early to mid stage ALK positive NSCLC patients. The results of two Phase III clinical trials showed that second-generation ALK targeted drugs, neoadjuvant and/or adjuvant therapy for ALK positive NSCLC, significantly prolonged DFS in patients, including increased pathological response rate, median response duration, and prolonged OS. For ALK positive advanced NSCLC patients who are resistant to second-generation ALK targeted drugs, there is currently limited exploration and there is an urgent need for new exploratory clinical studies.This trial aims to evaluate the effectiveness of Iruplinalkib neoadjuvant therapy for potentially resectable ALK positive non-small cell lung cancer. conditions: Potentially Resectable ALK Positive Non-Small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: All enrolled patients received Iruplinalkib neoadjuvant therapy. primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Iruplinalkib name: surgery measure: Objective response rate (ORR) measure: Pathologic complete response (PCR) rate measure: Major pathologic response (MPR) rate measure: Overall survival (OS) measure: Event-free survival (EFS) measure: Treatment-related adverse event (TRAE) measure: 5-year overall survival (OS) measure: 1-year event-free survival (EFS) rate measure: Health related quality of life (HRQol) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06282523 id: 2023-1773 id: A171600 type: OTHER domain: UW- Madison id: EDUC/COUNSELING PSYCH type: OTHER domain: UW- Madison id: Protocol Version 12/27/23 type: OTHER domain: UW- Madison briefTitle: Healthy Minds Comparison Study overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-06 date: 2024-06 date: 2024-02-28 date: 2024-04-25 name: University of Wisconsin, Madison class: OTHER briefSummary: The goal of this clinical trial is to understand the difference between two versions of the Healthy Minds application, a digital well-being program. The main question it aims to answer is the differences between versions of the Healthy Minds application and their effects on well-being.